Tag: investor

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI; the "Company" or “FTAI”) plans to announce its financial results for the second quarter 2025 after the closing of Nasdaq on Tuesday, July 29, 2025. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, https://www.ftaiaviation.com/.

According to Precedence Research, the global carbon credit market size is valued at USD 933.23 billion in 2025 and is expected to be worth USD 16,379.53 billion by 2034, growing at a robust CAGR of 37.68% from 2025 to 2034.

Hamilton, Bermuda, June 26, 2025 – Golar LNG Limited (the “Company”) (NASDAQ: GLNG) announces today the pricing of $500 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2030 (the “Notes”), in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company has also granted the initial purchasers of the Notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of the Notes in connection with the offering. The offering is expected to close on June 30, 2025, subject to the satisfaction of certain customary closing conditions.

TOKYO and NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that funds managed by its affiliates (the “Apollo Funds”) have agreed to sell their interest in MAFTEC Group Co., Ltd. (“MAFTEC” or the “Company”), a Japan based global leader in ultra-high temperature heat insulating solutions serving the automotive and industrial end-markets, to funds managed by Advantage Partners.

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy^® 2 mg (the trade name for neffy^® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.

COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN^® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women

Wereldhave N.V. (‘Wereldhave’) has signed its inaugural European Private Placement (EUPP) transaction, with Aegon Asset Management, securing a € 50 million loan with a tenor of ten years. The transaction, which settles on 27 June 2025, was agreed on competitive terms and follows multiple successful US Private Placement (USPP) transactions since 2011.